Darvadstrocel
| Clinical data | |
|---|---|
| Trade names | Alofisel |
| Other names | CX-601 |
| Routes of administration | Injection |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| DrugBank | |
| UNII | |
| KEGG | |
Darvadstrocel, sold under the brand name Alofisel, is a medication used to treat complex perianal fistulas in adults with non-active/mildly active luminal Crohn's disease when fistulas have shown an inadequate response to at least one conventional or biologic therapy.[1] It contains mesenchymal stem cells from fat tissue of adult donors.[2]
It was approved for use in the European Union in March 2018.[2] The approval was spearheaded by data published in the ADMIRE-CD trial.[2][3] Darvadstrocel was withdrawn from the EU market in December 2024.[4]
It was approved for use in Japan by Japan's Ministry of Health, Labour and Welfare (MHLW) in September 2021.[5]
Medical use
[edit]Darvadstrocel has been approved by the European Union for the treatment of adults with complex Crohn's perianal fistulas after conventional or biological medications have not worked.[2]
Mechanism of action
[edit]Darvadstrocel works by reducing inflammation and facilitating the growth of tissue in the fistula tract.[2][3]
History
[edit]ADMIRE-CD
[edit]The ADMIRE-CD trial was a phase III trial that assessed the safety and efficacy of darvadstrocel vs. placebo in adults with complex perianal fistulas with Crohn's disease.[3][6] The study randomized a total of 212 patients.[3] 107 patients were given darvadstrocel and 105 patients were given placebo.[3]
After one year, the study found darvadstrocel to be effective in closing external fistula openings, compared to placebo.[3] Patients taking darvadstrocel had a combined remission of 56.3% and clinical remission of 59.2%.[3] The placebo controls had a combined remission of 38.6% and clinical remission of 41.6%.[3]
INSPECT
[edit]Published in 2022, the INSPECT study is a retrospective study that evaluated the long-term effectiveness and safety of darvadstrocel in patients with perianal fistulas in Crohn's disease that were treated in the ADMIRE-CD trial.[7] The study data showed that darvadstrocel or the maintenance treatment used can have long term clinical remission in patients.[7]
ADMIRE-CD II
[edit]The phase III ADMIRE-CD II study, assessing the efficacy and safety of Alofisel (darvadstrocel) for the treatment of complex Crohn's perianal fistulas, did not meet its primary endpoint of combined remission at 24 weeks, based on topline data.
— [8]
Society and culture
[edit]Legal status
[edit]Darvadstrocel is approved for medical use in the European Union, Israel, Switzerland, Serbia, the United Kingdom, and Japan.[8] Darvadstrocel was withdrawn from the European Union market in December 2024.[4]
References
[edit]- ^ a b "Alofisel 5 million cells/mL suspension for injection - Summary of Product Characteristics (SmPC)". (emc). 12 February 2020. Archived from the original on 28 February 2020. Retrieved 27 February 2020.
- ^ a b c d e f "Alofisel EPAR". European Medicines Agency (EMA). Archived from the original on 11 August 2020. Retrieved 27 February 2020.
- ^ a b c d e f g h Panés J, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, et al. (April 2018). "Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease". Gastroenterology. 154 (5): 1334–1342.e4. doi:10.1053/j.gastro.2017.12.020. PMID 29277560.
{{cite journal}}: CS1 maint: overridden setting (link) - ^ a b "Alofisel withdrawn from the EU market". European Medicines Agency (EMA) (Press release). 13 December 2024. Retrieved 16 December 2024.
- ^ NS Healthcare Staff Writer (28 September 2021). "Takeda's Alofisel approved in Japan to treat fistulas in patients with Crohn's disease". NS Healthcare. Archived from the original on 30 November 2021. Retrieved 30 November 2021.
- ^ "Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease (ADMIRE-CD)". Clinicaltrials.gov. Archived from the original on 15 June 2012.
- ^ a b Panés J, Bouma G, Ferrante M, Kucharzik T, Nachury M, de la Portilla de Juan F, et al. (November 2022). "INSPECT: A Retrospective Study to Evaluate Long-term Effectiveness and Safety of Darvadstrocel in Patients With Perianal Fistulizing Crohn's Disease Treated in the ADMIRE-CD Trial". Inflammatory Bowel Diseases. 28 (11): 1737–1745. doi:10.1093/ibd/izab361. PMC 9629463. PMID 35099555.
{{cite journal}}: CS1 maint: overridden setting (link) - ^ a b "Takeda announces topline results of phase 3 ADMIRE-CD II trial of Alofisel". Takeda Pharmaceuticals (Press release). Retrieved 15 December 2024.
Further reading
[edit]- Kotze PG, Spinelli A, Warusavitarne J, Di Candido F, Sahnan K, Adegbola SO, et al. (February 2019). "Darvadstrocel for the treatment of patients with perianal fistulas in Crohn's disease". Drugs of Today. 55 (2): 95–105. doi:10.1358/dot.2019.55.2.2914336. PMID 30816884. S2CID 73513510.
- Meng ZW, Baumgart DC (June 2020). "Darvadstrocel for the treatment of perianal fistulas in Crohn's disease". Expert Review of Gastroenterology & Hepatology. 14 (6): 405–410. doi:10.1080/17474124.2020.1764349. PMID 32354239. S2CID 218474650.
- Pinho-Gomes AC, Cairns J (March 2022). "Evaluation of Advanced Therapy Medicinal Products by the National Institute for Health and Care Excellence (NICE): An Updated Review". PharmacoEconomics - Open. 6 (2): 147–167. doi:10.1007/s41669-021-00295-2. PMC 8864053. PMID 34415514.
- Scott LJ (December 2018). "Darvadstrocel: A Review in Treatment-Refractory Complex Perianal Fistulas in Crohn's Disease". BioDrugs. 32 (6): 627–634. doi:10.1007/s40259-018-0311-4. PMID 30298387. S2CID 52936920.
External links
[edit]- "Darvadstrocel for treating complex perianal fistulas in Crohn's disease". NICE. 9 January 2019.
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |